These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 11006018

  • 21. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K, Niwa O.
    Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].
    Liu YX, Fan DM, Xiong DS, Xu YF, Shao XF, Xu YS, Peng H, Yang M, Qin L, Zhu ZP, Yang CZ.
    Ai Zheng; 2003 Dec; 22(12):1249-53. PubMed ID: 14693045
    [Abstract] [Full Text] [Related]

  • 25. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
    Biddle WC, Pancook J, Goldrosen M, Han T, Foon KA, Vaickus L.
    Cancer Res; 1990 May 15; 50(10):2991-6. PubMed ID: 2334902
    [Abstract] [Full Text] [Related]

  • 26. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z, Freedman MS.
    Clin Immunol; 2008 Aug 15; 128(2):219-27. PubMed ID: 18501678
    [Abstract] [Full Text] [Related]

  • 27. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
    Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA.
    Clin Cancer Res; 2009 Apr 15; 15(8):2739-46. PubMed ID: 19351771
    [Abstract] [Full Text] [Related]

  • 28. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):151-60. PubMed ID: 16219319
    [Abstract] [Full Text] [Related]

  • 29. Mechanism of action of rituximab.
    Maloney DG.
    Anticancer Drugs; 2001 Jun 30; 12 Suppl 2():S1-4. PubMed ID: 11508930
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
    Liu Y, Zheng M, Lai Z, Xiong D, Fan D, Xu Y, Peng H, Shao X, Xu Y, Yang M, Wang J, Liu H, Xie Y, Yang C, Zhu Z.
    Cancer Lett; 2004 Mar 18; 205(2):143-53. PubMed ID: 15036646
    [Abstract] [Full Text] [Related]

  • 31. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R.
    Blood; 1997 Sep 15; 90(6):2188-95. PubMed ID: 9310469
    [Abstract] [Full Text] [Related]

  • 32. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 33. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.
    Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, Seto M, Morishima Y.
    Jpn J Cancer Res; 1998 Jul 01; 89(7):748-56. PubMed ID: 9738982
    [Abstract] [Full Text] [Related]

  • 34. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.
    Maeda T, Yamada Y, Tawara M, Yamasaki R, Yakata Y, Tsutsumi C, Onimaru Y, Kamihira S, Tomonaga M.
    Int J Hematol; 2001 Jul 01; 74(1):70-5. PubMed ID: 11530808
    [Abstract] [Full Text] [Related]

  • 35. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
    Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt-Wolf I.
    Cytokine; 2000 Jun 01; 12(6):756-61. PubMed ID: 10843759
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
    van der Kolk LE, de Haas M, Grillo-López AJ, Baars JW, van Oers MH.
    Leukemia; 2002 Apr 01; 16(4):693-9. PubMed ID: 11960351
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 01; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.